In view of results from the FIGHT-202 phase II clinical trial, pemigatinib—a selective FGFR1–3 inhibitor—received regulatory approval as a second-line treatment option in locally advanced or metastatic CCA with FGFR2 fusions or rearrangements [15]. Here, FGFR2 is linked to cholangiocarcinoma.